Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027

Loading news article.

Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 | WAPE

Article summary